[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Kansas City Heart Rhythm Research Foundation\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":352},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,17,0,[8,40,61,82,102,121,137,157,177,193,211,229,247,266,291,312,327],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":39},"100576328","assessing-the-neurological-outcomes-after-atrial-fibrillation-ablation-for-rhythm-control-100576328",false,"NCT06783868","Assessing the Neurological Outcomes After Atrial Fibrillation Ablation for Rhythm Control","Randomized Control Study to Assess the Neurological Outcomes After Atrial Fibrillation Ablation for Rhythm Control vs Routine Medication Therapy in Patients With Recent Stroke: SAVE STROKE Phase II Study","SAVE STROKE II","Inclusion Criteria:\n\n* Ages \\>18 and able to provide consent.\n* Presenting with an acute stroke and new-onset AF\n* Modified RANKIN score (mRS) \\\u003C 6\n* Must be able to undergo some form of cardiac monitoring \\[implantable loop recorder (ILR), electrocardiogram (ECG), Holter monitor\\] to quantify AF burden\n\nExclusion Criteria:\n\n* Patients \\\u003C 18 years of age\n* Unable to provide consent, including mRS = 6.\n* Not able to read and write at an 8th-grade level \\[to complete AFEQT and EQ-5D surveys\\]\n* Positive B-hCG\n* Will not follow up with our practice\u002Fclinic afterward.\n* Cannot tolerate OAC or AAD for any reason.\n* Cannot undergo CA for any reason.","ALL","18 Years",{"count":20,"type":21},100,"ESTIMATED","OBSERVATIONAL","A prospective, non-blinded, multi-center study to assess the impact of early Catheter Ablation (CA) in patients with a new diagnosis of Atrial Fibrillation(AF) at the time of stroke. 100 patients will be enrolled.",[25,26],"Atrial Fibrillation","Stroke","NOT_YET_RECRUITING","2025-08-27",{"date":30,"type":31},"2025-08-28","ACTUAL",{"date":33,"type":21},"2025-10",{"date":35,"type":21},"2027-06",{"name":37,"class":38},"Kansas City Heart Rhythm Research Foundation","OTHER",7,{"id":41,"slug":42,"hasResults":11,"nctId":43,"briefTitle":44,"officialTitle":45,"acronym":4,"eligibilityCriteria":46,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":47,"targetDuration":4,"studyType":48,"phases":49,"briefSummary":51,"conditions":52,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":54,"startDateStruct":55,"completionDateStruct":57,"leadSponsor":59,"locationsCount":60},"100567797","development-and-validation-of-the-kansas-city-cardiac-dysautonomia-questionnaire-kcdysq-100567797","NCT06672861","Development and Validation of the Kansas City Cardiac Dysautonomia Questionnaire (KCDysQ)","Development and Validation of the Kansas City Cardiac Dysautonomia Questionnaire (KCDysQ) in Patients With Postural Orthostatic Tachycardia Syndrome, Inappropriate Sinus Tachycardia, and Other Disorders of Cardiac Dysautonomia","Inclusion criteria:\n\nPatients with a Diagnosis of POTS, IST, or vasovagal syncope\n\nExclusion criteria:\n\nPatients with comorbid chronic conditions causing significant impairments in quality of life, defined as:\n\n* NYHA Class III or IV Heart Failure\n* COPD GOLD 3 or 4, Group C or D\n* Any patients with current malignancy not in remission\n* Any patient with history of Autoimmune disease requiring chronic steroid therapy or immunomodulatory agents: Rheumatoid Arthritis, Lupus, Sarcoidosis, Psoriasis All patients with ESRD requiring hemodialysis All patients with cirrhosis of any origin Any patients with solid organ or bone marrow transplant requiring immunosuppressive therapy",{"count":20,"type":21},"INTERVENTIONAL",[50],"NA","Main aim will be to compare in patients with cardiac dysautonomia, newly developed disease specific questionnaire to established generalized SF-36 and EQ-5d questionnaires, as there are no disease specific questionnaires for comparison. These novel and established questionnaires will then be compared among groups who have relatively stable disease or stable symptoms with patients who will be expected to have a change in symptoms and QoL.",[53],"Cardiac Dysautonomia",{"date":30,"type":31},{"date":56,"type":21},"2026-01",{"date":58,"type":21},"2026-08",{"name":37,"class":38},3,{"id":62,"slug":63,"hasResults":11,"nctId":64,"briefTitle":65,"officialTitle":65,"acronym":4,"eligibilityCriteria":66,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":67,"enrollmentInfo":68,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":70,"conditions":71,"keywords":4,"overallStatus":74,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":75,"startDateStruct":76,"completionDateStruct":78,"leadSponsor":80,"locationsCount":81},"100538329","autonomic-dysfunction-in-patients-following-bariatric-surgery-the-adipose-study-100538329","NCT06289413","Autonomic Dysfunction in Patients Following Bariatric Surgery: The ADiPOSE Study","Inclusion Criteria:\n\n* Between the age of 18 - 85 years\n* Can provide consent\n* Negative urine B-hCG\n* Continued follow-up with the bariatric surgery team.\n* BS includes one of the following: gastric bypass, sleeve gastrectomy, and biliopancreatic diversion with duodenal switch.\n* Phase I: Underwent BS within the last 3 years\n* Phase II: Will undergo BS within the next 3 months or underwent BS in the last 30 days\n\nExclusion Criteria:\n\n* Unable to provide consent\n* Pregnant or breastfeeding\n* BMI \\\u003C 35\n* Revision surgery of one of the following BS from above\n* Prior history of autonomic dysfunction prior to BS\n* Developed AD 72 months post-procedure\n* No evidence of AD\u002FOI","85 Years",{"count":69,"type":21},400,"Observational two phase, retrospective and prospective registry study to assess the prevalence of and characterize outcomes of autonomic dysfunction (AD) in patients who undergo bariatric surgery (BS) and to better define the underlying pathophysiology of AD following BS.",[72,73],"Autonomic Dysfunction","Orthostatic Intolerance","RECRUITING",{"date":30,"type":31},{"date":77,"type":31},"2024-02-12",{"date":79,"type":21},"2025-12",{"name":37,"class":38},8,{"id":83,"slug":84,"hasResults":11,"nctId":85,"briefTitle":86,"officialTitle":87,"acronym":4,"eligibilityCriteria":88,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":89,"enrollmentInfo":90,"targetDuration":4,"studyType":48,"phases":92,"briefSummary":93,"conditions":94,"keywords":4,"overallStatus":74,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":95,"startDateStruct":96,"completionDateStruct":98,"leadSponsor":100,"locationsCount":101},"100520837","use-of-4d-ice-in-conjunction-with-tee-for-left-atrial-appendage-closure-100520837","NCT06061757","Use of 4D-ICE in Conjunction With TEE for Left Atrial Appendage Closure","Use of 4D Intracardiac Echocardiography (4D-ICE) in Conjunction With Transesophageal Echocardiography (TEE) for Left Atrial Appendage Closure (LAAC)","Inclusion Criteria:\n\n* Male\u002FFemales\n* Age:18-80 years\n* History of Atrial Fibrillation\u002FAtrial flutter\n* Will have endocardial Left Atrial Appendage Closure (LAAC) with an Amplatzer Amulet or WATCHMAN FLX device\n\nExclusion Criteria:\n\n* Inability or unwillingness of an individual to give written informed consent\n* Patient not following with our practice after the procedure\n* Complex anatomy for endocardial LAAC\n* Thrombus in LAA\n* Patients with pericardial effusion in pre-op TEE\u002FCCTA\n* Patients currently pregnant (Serum beta HCG completed when labs obtained for the procedure are completed)","80 Years",{"count":91,"type":21},52,[50],"This is a prospective, single center, non-randomized study with two parallel arms intended to study if 4D Intracardiac echocardiography (4D-ICE) (Nuvision, Nuvera TM) will provide better visualization of the anatomical landmarks from the larger imaging volume and provide optimal intra procedural guidance similar to Transesophageal echocardiography (TEE) (GE 6VT-D ULTRASOUND TRANSDUCER) for Left atrial appendage closure (LAAC). The study will enroll approximately 52 subjects and will be followed through 12 months.",[25,26],{"date":30,"type":31},{"date":97,"type":31},"2023-05-10",{"date":99,"type":21},"2025-12-31",{"name":37,"class":38},1,{"id":103,"slug":104,"hasResults":11,"nctId":105,"briefTitle":106,"officialTitle":107,"acronym":4,"eligibilityCriteria":108,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":109,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":111,"conditions":112,"keywords":4,"overallStatus":74,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":115,"startDateStruct":116,"completionDateStruct":118,"leadSponsor":119,"locationsCount":120},"100520744","role-of-novel-ilr-in-the-management-of-pvcs-100520744","NCT06060548","Role of Novel ILR in the Management of PVCs","Role of a Novel Implantable Loop Recorder in the Management of Premature Ventricular Contractions","Inclusion Criteria:\n\n* Patients \\> 18 years of age\n* Have a Medtronic LINQ II ILR\n* Willing and able to give written informed consent\n\nExclusion Criteria:\n\n* History of myocardial infarction\n* Significant flow-limiting coronary artery disease (≥50% stenosis) on invasive coronary angiography or Computed tomography angiography (CTA).\n* History of cardiac arrest\n* With existing implantable defibrillators\n* Currently pregnant",{"count":110,"type":21},50,"This prospective, observational study is a single center clinical registry of patients referred for management of symptomatic or asymptomatic Premature Ventricular Contractions (PVCs). Subjects will be followed through 12 months. The study will enroll approximately 50 patients.",[113,114],"PVC - Premature Ventricular Contraction","Myocarditis",{"date":30,"type":31},{"date":117,"type":31},"2022-04-20",{"date":79,"type":21},{"name":37,"class":38},6,{"id":122,"slug":123,"hasResults":11,"nctId":124,"briefTitle":125,"officialTitle":126,"acronym":4,"eligibilityCriteria":127,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":128,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":129,"conditions":130,"keywords":4,"overallStatus":74,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":132,"startDateStruct":133,"completionDateStruct":135,"leadSponsor":136,"locationsCount":101},"100521902","long-term-outcomes-of-laa-contrast-flow-in-ct-scans-after-endocardial-laa-closure-the-cf-ct-registry-100521902","NCT06075628","Long-Term Outcomes of LAA Contrast Flow in CT Scans After Endocardial LAA Closure: The CF-CT Registry","Long-Term Outcomes of Left Atrial Appendage Contrast Flow in CT Scans After Endocardial LAA Closure: The CF-CT Registry","Inclusion Criteria:\n\n* Subjects must be at least 18 years of age.\n* Subjects underwent LAA closure with Watchman\u002FWatchman FLX or Amplatzer Amulet at our institution from January 2019 till June 2022\n\nExclusion Criteria:\n\n* No definite exclusion criteria are defined for the study as all patients with Watchman-FLX or Amplatzer Amulet will be included in the study.",{"count":20,"type":21},"This study is intended to assess the incidence and correlation to the development of peri-device leaks (PDLs), device related thrombosis (DRTs) and cerebral vascular accident (CVA)\u002Ftransient ischemic attacks (TIAs) in association with left atrial appendage contrast flow (LAA-CF). It will be a multi-center, retrospective study. Approximately 100 subject charts will be reviewed.",[25,131],"Ischemic Stroke, Acute",{"date":30,"type":31},{"date":134,"type":31},"2023-07-24",{"date":79,"type":21},{"name":37,"class":38},{"id":138,"slug":139,"hasResults":11,"nctId":140,"briefTitle":141,"officialTitle":142,"acronym":4,"eligibilityCriteria":143,"healthyVolunteers":144,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":145,"targetDuration":4,"studyType":48,"phases":147,"briefSummary":149,"conditions":150,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":152,"startDateStruct":153,"completionDateStruct":154,"leadSponsor":156,"locationsCount":60},"100483512","phase-1-effectiveness-of-bupivacaine-ketorolac-ketamine-vs-bupivacaine-alone-in-reducing-postoperative-pocket-pain-100483512","NCT05575999","Effectiveness of Bupivacaine, Ketorolac, Ketamine, vs Bupivacaine Alone in Reducing Postoperative Pocket Pain","Pain Management in Cardiac Implantable Electronic Device Insertion; Effectiveness of Bupivacaine, Ketorolac, Ketamine, vs Bupivacaine Alone in Reducing Postoperative Pocket Pain","Inclusion Criteria:\n\n* Both male and female patients\n* Patients older than 18 years of age\n* Patients undergoing new CIED (ICD, pacemaker, CRT-D or CRT-P)\n* Patients willing to participate in the study\n\nExclusion Criteria:\n\n* Patients with prior history of allergic reaction to any component of the drug; bupivacaine, ketorolac, or ketamine\n* Pregnant or breastfeeding patients\n* Prisoners\n* Patients younger than 18 years of age\n* Patients not willing to participate in the study\n* Patients deemed not suitable or unstable for the study as per physician's discretion",true,{"count":146,"type":21},200,[148],"PHASE1","Bupivacaine is the most widely used local anesthetic agent across majority of the Cardiac Implantable Electronic device (CIED) implant procedures in the United States. It is hypothesized that the combination of Bupivacaine-Ketorolac-Ketamine (BKK) is more effective in alleviating perioperative and postoperative pain as compared to the use of bupivacaine alone.\n\nA few studies have been done to look for the effectiveness of BKK in abdominal surgical procedures. However, no study has been done to evaluate its efficacy and effectiveness in patients undergoing CIED insertion.",[151],"Pain Management",{"date":30,"type":31},{"date":56,"type":21},{"date":155,"type":21},"2026-12",{"name":37,"class":38},{"id":158,"slug":159,"hasResults":11,"nctId":160,"briefTitle":161,"officialTitle":162,"acronym":4,"eligibilityCriteria":163,"healthyVolunteers":11,"sex":17,"minAge":164,"maxAge":165,"enrollmentInfo":166,"targetDuration":4,"studyType":48,"phases":167,"briefSummary":168,"conditions":169,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":170,"startDateStruct":171,"completionDateStruct":173,"leadSponsor":175,"locationsCount":176},"100474979","impact-of-intravenous-caffeine-on-atrial-electrical-properties-and-potential-arrythmia-induction-100474979","NCT05464940","Impact of Intravenous Caffeine on Atrial Electrical Properties and Potential Arrythmia Induction","Impact of Intravenous Caffeine on Atrial Electrical Properties and Potential Arrythmia Induction in Patients With Paroxysmal Atrial Fibrillation: The COFFEE-AF Trial","Inclusion Criteria:\n\nAll adult patients from 21-90 years of age with new onset Paroxysmal Atrial Fibrillation presenting in sinus rhythm or AF of recent onset (the latter confirmed by sinus rhythm documented no more than 1 week prior) undergoing AF ablation will be included in the study.\n\nExclusion Criteria:\n\nPatients will be excluded if any of the following were identified:\n\n1. History of substance abuse or alcoholism.\n2. Left ventricular ejection fraction \\\u003C50%.\n3. Liver dysfunction.\n4. Pregnancy.\n5. Inability to give informed consent.\n6. Amiodarone uses within 1 month prior to procedure.\n7. AAD use within 24 h prior to the procedure\n8. Severe intolerance to caffeine.","21 Years","90 Years",{"count":20,"type":21},[50],"This \"How caffeine Induces Atrial Tachyarrhythmias\" trial will be a multi-center, randomized, double-blinded trial of intravenous caffeine versus placebo among patients undergoing pulmonary vein isolation procedures for Atrial Fibrillation(AF).",[25],{"date":30,"type":31},{"date":172,"type":21},"2025-09",{"date":174,"type":21},"2026-06",{"name":37,"class":38},9,{"id":178,"slug":179,"hasResults":11,"nctId":180,"briefTitle":181,"officialTitle":182,"acronym":4,"eligibilityCriteria":183,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":184,"targetDuration":4,"studyType":48,"phases":186,"briefSummary":187,"conditions":188,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":189,"startDateStruct":190,"completionDateStruct":191,"leadSponsor":192,"locationsCount":39},"100474946","impact-of-steerable-delivery-sheaths-on-successful-closure-of-la-a-with-amulet-100474946","NCT05464511","Impact of Steerable Delivery Sheaths on Successful Closure of LA A With AMULET","Impact of Steerable Delivery Sheaths on Successful Closure of Left Atrial Appendage With AMULET Dual Mechanism Closure Device (STEER-CLOSE Study)","Inclusion Criteria:\n\nPatients with atrial fibrillation who meets the indication\u002Fcriteria for left atrial appendage occlusion and undergoing implantation of Amplatzer™ Amulet™ Left Atrial Appendage Occluder device\n\nExclusion Criteria:\n\n* Patient been\u002Fbeing implanted with device other than Amplatzer™ Amulet™ Left Atrial Appendage Occluder\n* Pregnant or breastfeeding patients\n* Prisoners\n* Patients not willing to participate in the study",{"count":185,"type":21},300,[50],"The novel Amplatzer steerable delivery sheath (Abbott Vascular) is found to be safe and effective in performing LAAO procedure. However, the procedural outcomes have not been compared with the traditional non-steerable fixed curve sheath. In this study investigators aim to compare the outcome of patients undergoing left atrial appendage occlusion with the dual mechanism closure Amulet device using non-steerable fixed curve sheath versus a novel steerable sheath.",[25,26],{"date":30,"type":31},{"date":56,"type":21},{"date":155,"type":21},{"name":37,"class":38},{"id":194,"slug":195,"hasResults":11,"nctId":196,"briefTitle":197,"officialTitle":197,"acronym":198,"eligibilityCriteria":199,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":200,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":201,"conditions":202,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":205,"startDateStruct":207,"completionDateStruct":208,"leadSponsor":210,"locationsCount":101},"100451457","myocarditis-causing-premature-ventricular-contractionsinsights-from-the-maveric-registry-100451457","NCT05158751","Myocarditis Causing Premature Ventricular Contractions:Insights From the MAVERIC Registry","MAVERIC","Inclusion Criteria:\n\n* Patients \\> 18 years of age with mono-morphic or polymorphic PVC burden of ≥5000 in 24 hours.\n* Non-sustained VT was defined as ≥3 more consecutive beats lasting \\\u003C30 seconds\n\nExclusion Criteria:\n\n* History of myocardial infarction,\n* Significant flow-limiting coronary artery disease (≥50% stenosis) on invasive coronary angiography or CT angiography,\n* History of revascularization,\n* Significant symptomatic atrial arrhythmias associated with LV dysfunction,\n* Severe valvular disease,\n* Cardiomyopathy attributed to toxins such as alcohol and illicit drugs,\n* History of cardiac arrest,\n* History of channelopathies or inherited arrhythmias.",{"count":20,"type":21},"To assess potential link between unrecognized myocardial inflammation (myocarditis) and premature ventricular contractions (PVCs) associated with and without reduced Left ventricular ejection fraction (LVEF) through comprehensive diagnostic work up.",[114,203,204],"Premature Ventricular Contractions","Ventricular Tachycardia (VT)",{"date":206,"type":31},"2025-09-04",{"date":56,"type":21},{"date":209,"type":21},"2026-05",{"name":37,"class":38},{"id":212,"slug":213,"hasResults":11,"nctId":214,"briefTitle":215,"officialTitle":216,"acronym":4,"eligibilityCriteria":217,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":218,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":220,"conditions":221,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":224,"startDateStruct":225,"completionDateStruct":226,"leadSponsor":227,"locationsCount":228},"100449964","the-orchestrate-myocarditis-registry-100449964","NCT05139329","The ORCHESTRATE-Myocarditis Registry","Observational Registry of Ischemia Negative Chest Pain as the Presentation of Underlying Myocarditis: the ORCHESTRATE-Myocarditis Registry","Inclusion criteria\n\n1. Age \\>18 years\n2. Patients with a presentation of typical or atypical chest pain (ICD-10 Code R07.89, R07. 9)\n3. Patients with a negative ischemic workup: (including Coronary Artery Calcium Scoring\u002FCTA, MPI, Nuclear Stress test, LHC\u002Fangiography showing anything greater than \"non-obstructive CAD\")\n\nExclusion criteria\n\n1. Patients with any evidence of positive ischemic workup as the cause of typical\u002Fatypical chest pain (as seen on Coronary Artery Calcium Scoring\u002FCTA, MPI, Nuclear Stress test, LHC\u002Fangiography)\n2. Previously documented history of Prinzmetal angina or coronary vasospasm\n3. History of prior myocardial infarction\n4. History of any prior CAD with severity greater than \"non-obstructive CAD\" in all 3 coronary arteries\n5. History of LVEF\\\u003C40%\n6. Previously documented history of pericarditis\n7. Previously documented history of costochondritis",{"count":219,"type":21},382,"A retrospective, observational study consisting of patients who presents with typical\u002Fatypical chest pain and have an ensuing negative ischemic evaluation",[114,222,223],"Ischemia","Chest Pain",{"date":30,"type":31},{"date":56,"type":21},{"date":209,"type":21},{"name":37,"class":38},4,{"id":230,"slug":231,"hasResults":11,"nctId":232,"briefTitle":233,"officialTitle":233,"acronym":4,"eligibilityCriteria":234,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":235,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":236,"conditions":237,"keywords":4,"overallStatus":74,"whyStopped":4,"lastUpdateSubmitDate":239,"lastUpdatePostDateStruct":240,"startDateStruct":242,"completionDateStruct":244,"leadSponsor":246,"locationsCount":101},"100542409","conduction-system-vs-surgical-left-ventricular-epicardial-pacing-for-coronary-sinus-lead-failure-100542409","NCT06342492","Conduction System Vs Surgical Left Ventricular Epicardial Pacing For Coronary Sinus Lead Failure","Inclusion Criteria:\n\n* All patients older than 18 years of age\n* Patients with HFrEF that underwent BVP-CRT\n* Experienced CS lead failure, whether initial or recurrent, subsequently replaced with transthoracic epicardial lead placement or CSP\n* Underwent Medtronic, Boston Scientific, or Abbott lead placement\n\nExclusion Criteria:\n\n* Patients younger than 18 years of age\n* Transthoracic epicardial lead placement or CSP performed as the initial approach or for other reasons than lead replacement\n* Those for which CRT no longer provides symptom relief or mortality benefit.",{"count":20,"type":21},"This a single-center, retrospective, observational study of patients that undergo coronary sinus(CS) lead revision, comparing epicardial lead placement to coronary sinus pacing(CSP) in those that had lead failure.",[238],"Heart Failure With Reduced Ejection Fraction","2024-10-25",{"date":241,"type":31},"2024-10-28",{"date":243,"type":31},"2023-11-07",{"date":245,"type":21},"2024-12",{"name":37,"class":38},{"id":248,"slug":249,"hasResults":11,"nctId":250,"briefTitle":251,"officialTitle":252,"acronym":4,"eligibilityCriteria":253,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":254,"targetDuration":4,"studyType":48,"phases":256,"briefSummary":257,"conditions":258,"keywords":4,"overallStatus":74,"whyStopped":4,"lastUpdateSubmitDate":239,"lastUpdatePostDateStruct":260,"startDateStruct":262,"completionDateStruct":264,"leadSponsor":265,"locationsCount":120},"100522139","vascular-closure-with-a-device-compared-to-manual-compression-after-atrial-fibrillation-ablation-the-locket-ii-study-100522139","NCT06078735","Vascular Closure With a Device Compared to Manual Compression After Atrial Fibrillation Ablation: The LockeT II Study","Vascular Closure With Novel Ergonomic External Compression Device Compared to Manual Compression After Atrial Fibrillation Ablation: The LockeT II Study","Inclusion Criteria:\n\n* Must be at least 18 years of age\n* Be able to provide consent\n* Presenting for planned procedures that require percutaneous venous punctures, such as atrial fibrillation radiofrequency ablation, and where the physician utilizes a LockeT device or MC to close the wound.\n\nExclusion Criteria:\n\n* Under the age of 18\n* Unable to or unwilling to provide consent\n* Cannot comply with study requirements\n* Not undergoing procedures that require a percutaneous venous puncture or planned access to the left atrium and\u002For ventricle\n* Subjects whose physician does not use LockeT or MC to close the venous puncture.\n* Patient is currently pregnant, as evidenced by positive urine Beta-HCG. (Urine Beta Human chorionic gonadotropin (HCG) will be checked in all females of the reproductive age group).\n* If the physician detects a formed hematoma prior to venous closure, that patient will be excluded from the study.",{"count":255,"type":21},110,[50],"The LockeT II study is a single center, prospective randomized study. It is intended to study the effectiveness of using LockeT device to gain hemostasis after venous procedures as compared to Manual Compression (MC). Approximately 110 patients will be enrolled.",[25,259],"Hemostasis",{"date":261,"type":31},"2024-10-29",{"date":263,"type":31},"2023-10-02",{"date":245,"type":21},{"name":37,"class":38},{"id":267,"slug":268,"hasResults":11,"nctId":269,"briefTitle":270,"officialTitle":271,"acronym":4,"eligibilityCriteria":272,"healthyVolunteers":11,"sex":17,"minAge":273,"maxAge":274,"enrollmentInfo":275,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":277,"conditions":278,"keywords":280,"overallStatus":74,"whyStopped":4,"lastUpdateSubmitDate":283,"lastUpdatePostDateStruct":284,"startDateStruct":286,"completionDateStruct":288,"leadSponsor":290,"locationsCount":101},"100400418","hs-students-mandatory-universal-student-instruction-in-cpr-appraised-learning--is-the-mandate-working-100400418","NCT04493970","HS Students Mandatory Universal Student Instruction in CPR Appraised Learning- Is the Mandate Working?","Assessment of Factors Impacting High School Students Mandatory Universal Student Instruction in Cardiopulmonary Resuscitation Appraised Learning- Is the Mandate Working? (The High School MUSICAL Study)","Inclusion Criteria:\n\n* High school students completing voluntary survey\n\nExclusion Criteria:\n\n* Inability to give consent\n* Inability to complete survey","12 Years","25 Years",{"count":276,"type":21},5000,"This study will help to provide better input to state health and education departments to improve the processes for CPR education. This will also help the EP council explore the opportunities to partner with other professional societies and other stake holders that have interest in this topic. Engagement of private-public partnerships for improving overall CPR education.",[279],"Sudden Cardiac Arrest",[281,282],"CPR Education","High School Students","2024-10-23",{"date":285,"type":31},"2024-10-26",{"date":287,"type":31},"2021-02-26",{"date":289,"type":21},"2024-10",{"name":37,"class":38},{"id":292,"slug":293,"hasResults":11,"nctId":294,"briefTitle":295,"officialTitle":295,"acronym":4,"eligibilityCriteria":296,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":297,"targetDuration":298,"studyType":22,"phases":4,"briefSummary":299,"conditions":300,"keywords":4,"overallStatus":74,"whyStopped":4,"lastUpdateSubmitDate":304,"lastUpdatePostDateStruct":305,"startDateStruct":307,"completionDateStruct":309,"leadSponsor":310,"locationsCount":311},"100520375","long-term-evaluation-of-cardiac-arrhythmias-after-transcatheter-aortic-valve-implantation--the-locate-registry-100520375","NCT06055751","Long Term Evaluation of Cardiac Arrhythmias After Transcatheter Aortic Valve Implantation -The LOCATE Registry","Inclusion Criteria:\n\n* Patients \\> 18 years of age with severe aortic stenosis that undergo TAVI for severe aortic stenosis that develop any one of the following conduction system abnormalities on the immediate post procedural or post operative ECG and have undergone ILR implantation for long-term monitoring of these conditions:\n* New left bundle branch block (QRS \\>120ms)\n* New first degree AV block (PR\\>200ms) or worsening of pre-existing first-degree AV block by \\>30ms\n* New right bundle branch block (QRS\\>120ms)\n* Intra-procedural 2:1 or higher-grade AV block with spontaneous improvement within 24 hours\n\nExclusion Criteria:\n\n* Patients with high grade or complete AV block post TAVI needing urgent pacemakers\n* Patient with existing cardiac implantable electronic devices (CIEDs)\n* Patients having a particular medical condition that dictates that they cannot tolerate subcutaneous, chronically-inserted device\n* Patient is currently pregnant as evidenced by urine positive Beta-HCG. (Urine Beta human chorionic gonadotropin (HCG) will be checked in all females of the reproductive age group).\n* Patients not willing to sign the consent, lacks the capacity to sign the consent or revoke the consent after signing will be excluded",{"count":110,"type":21},"12 Months","The purpose of the Long term Evaluation of Cardiac Arrhythmias after Transcatheter Aortic Valve Implantation (LOCATE) Registry is to perform long-term ambulatory monitoring of patients with severe aortic stenosis who undergo trans-catheter aortic valve implantation (TAVI) and develop new onset conduction system abnormalities post-procedure that do not require urgent permanent pacemaker (PPM) implantation. The primary objectives of this study are to assess the incidence of late onset heart block necessitating PPM implantation and to evaluate the incidence of new onset atrial fibrillation (AF) following TAVI. This study aims to provide valuable insights into the long-term cardiac health of TAVI patients and inform the development of improved treatment strategies for aortic stenosis patients with conduction system abnormalities.",[301,302,303],"Aortic Stenosis","Atrial Fibrillation New Onset","Heart Block","2024-10-14",{"date":306,"type":31},"2024-10-16",{"date":308,"type":31},"2023-09-22",{"date":79,"type":21},{"name":37,"class":38},2,{"id":313,"slug":314,"hasResults":11,"nctId":315,"briefTitle":316,"officialTitle":316,"acronym":4,"eligibilityCriteria":317,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":89,"enrollmentInfo":318,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":319,"conditions":320,"keywords":4,"overallStatus":74,"whyStopped":4,"lastUpdateSubmitDate":304,"lastUpdatePostDateStruct":322,"startDateStruct":323,"completionDateStruct":324,"leadSponsor":326,"locationsCount":228},"100502777","observational-study-to-examine-the-procedural-and-outcomes-of-af-ablation-assisted-by-star-apollo-mapping-system-100502777","NCT05826665","Observational Study to Examine the Procedural and Outcomes of AF Ablation Assisted by STAR Apollo™ Mapping System","Inclusion Criteria:\n\n* Indication for ablation of persistent AF\n* Age \\>18 years\n* Persistent AF \\>7 days and total continuous duration \\\u003C2 years\n* Patients have previously undergone pulmonary vein isolation, using any technique and have had AF recurrence.\n* Patients have limited additional ablation at their first procedure (e.g. right atrial flutter line).\n\nExclusion Criteria:\n\n* Patients with previous ablation in more than one region of the left atrium in addition to the pulmonary veins.\n* Patients with longstanding persistent AF (continuous duration \\>2 years) or significant substrate (mitral valve disease, scarring, very dilated atria \\>50mm).\n* Creatinine clearance estimated glomerular filtration rate (eGFR) \\\u003C30mls\u002Fmin\n* Contraindication to anticoagulation",{"count":146,"type":21},"STAR Apollo Mapping System is an FDA cleared mapping technology that can analyze the signals collected during the ablation procedure on the 3D mapping system and give the physician further insight into the AF activation patterns which may assist them in identifying areas responsible for maintaining Atrial Fibrillation (AF). The STAR Apollo Mapping System system allows clinicians, after treating the Pulmonary Veins (PV), to collect data from the atria during clinical AF procedures using standard FDA cleared catheters and devices. This study aims to examine the impact of the STAR Apollo Mapping System on procedural and acute outcomes in a multicenter observational study.",[321],"Persistent Atrial Fibrillation",{"date":306,"type":31},{"date":263,"type":31},{"date":325,"type":21},"2025-07-31",{"name":37,"class":38},{"id":328,"slug":329,"hasResults":11,"nctId":330,"briefTitle":331,"officialTitle":332,"acronym":333,"eligibilityCriteria":334,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":335,"enrollmentInfo":336,"targetDuration":4,"studyType":48,"phases":338,"briefSummary":339,"conditions":340,"keywords":341,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":344,"lastUpdatePostDateStruct":345,"startDateStruct":347,"completionDateStruct":349,"leadSponsor":351,"locationsCount":4},"100551870","assessing-the-safety-and-efficacy-of-the-lambre-plus-device-100551870","NCT06465706","Assessing the Safety and Efficacy of the LAmbre™ Plus Device","A Prospective, Multicenter, Randomized Controlled Trial Assessing the Safety and Efficacy of the LAmbre™ Plus Left Atrial Appendage Closure System to REDUCE the Risk of Thromboembolism in Patients With Non-Valvular Atrial Fibrillation","REDUCE-AF","Inclusion Criteria:\n\n* The patient is a male or non-pregnant female ≥18 years of age\n* The patient has documented paroxysmal, persistent, or permanent non- valvular atrial fibrillation\n* The patient has a CHADS2 score ≥ 2 or a CHA2DS2-VASc score of ≥ 3, and is recommended for oral anticoagulation therapy\n* The patient is deemed by their physician to be suitable for short-term warfarin therapy, but there is an appropriate rationale for seeking a non-pharmacologic alternative to oral anticoagulation\n* The patient is deemed suitable for LAA closure by a multidisciplinary heart team, including at least 1 investigator (e.g. cardiologists) and 1 clinician not involved as part of the procedure team using a shared decision making process, and this determination has been documented in the patient's medical record\n* The patient is willing and able to comply with protocol-specified treatment and follow-up evaluations\n* The patient (or his or her legally authorized representative) has been informed of the nature of the study, agrees to its provisions, and has been provided written informed consent approved by the appropriate Institutional Review Board (IRB) or Ethics Committee (EC)\n\nExclusion Criteria:\n\n* Pregnant or nursing patients and those who plan pregnancy in the period up to 1 year following index procedure. Female patients of childbearing potential must have a negative pregnancy test done within 7 days prior to index procedure per site standard test.\n* Patients with atrial fibrillation that is defined by a single occurrence, or that is transient or reversible (e.g., secondary to CABG, an interventional procedure, pneumonia, or hyperthyroidism)\n* Patients who require long-term anticoagulation for a condition other than atrial fibrillation\n* Patients with an indication for chronic P2Y12 platelet inhibition therapy\n* Patients not suitable for short term warfarin (including due to bleeding diathesis or coagulopathy or absolute contraindication warfarin) or who will refuse transfusion\n* Patients with rheumatic mitral valve disease, known severe aortic stenosis requiring surgical or percutaneous valve replacement, or existing mechanical valve prosthesis\n* Active infection with bacteremia\n* Known hypersensitivity or contraindication to aspirin, clopidogrel, heparin\u002Fbivalirudin, any device material or component (nitinol, nickel, titanium, PET), and\u002For contrast sensitivity that cannot be adequately pre-medicated\n* Anatomic conditions that would prevent performance of the LAA occlusion procedure (e.g., prior atrial septal defect \\[ASD\\] or patient foramen ovale \\[PFO\\] surgical repair or implanted closure device, or obliterated left atrial appendage)\n* Recent (within 30 days pre-procedure) or planned (within 60 days post- procedure) cardiac or non-cardiac interventional or surgical procedure (e.g., cardioversion, ablation, percutaneous coronary intervention, cataract surgery, etc.)\n* Recent (within 90 days pre-procedure) stroke, transient ischemic attack, or myocardial infarction\n* Severe heart failure (New York Heart Association Class IV)\n* Known asymptomatic carotid artery disease with\\>70% diameter stenosis OR symptomatic carotid disease (\\>50% diameter stenosis with ipsilateral stroke or TIA). Subjects with prior carotid endarterectomy or carotid stent placement may be enrolled, provided that known diameter stenosis is \\\u003C50%.\n* Past or pending heart or any other organ transplant, or on the waiting list for any organ transplant\n* Known other medical illness or known history of substance abuse that may cause non-compliance with the protocol, confound data interpretation, or is associated with a life expectancy of less than 2 years\n* Current participation in another investigational drug or device study Echocardiographic Exclusion Criteria\n* Left atrial appendage anatomy cannot accommodate either the LAmbre Plus LAAO device or the Control device per manufacturer IFU (e.g., the anatomy and sizing must be for both device to be enrolled in the trial or maximum LAAO length \\\u003C maximum ostium width by TEE)\n* LVEF \\\u003C30%\n* Intracardiac thrombus or dense spontaneous echo contrast, as visualized by TEE within 2 days prior to implant\n* Moderate or large circumferential pericardial effusion \\>10 mm or symptomatic pericardial effusion, signs or symptoms of acute or chronic pericarditis, or evidence of tamponade physiology. In the event of a treatable pericardial effusion, the subject may undergo implantation at a later time after it is adequately treated.\n* Atrial septal defect that warrants closure.\n* Presence of a high risk patent foramen ovale (PFO), defined as an atrial septal aneurysm (excursion \\>15 mm or length \\>15 mm) or large shunt (early, within 3 beats and\u002For substantial passage of bubbles)\n* Moderate or severe mitral valve stenosis (mitral valve area \\\u003C1.5 cm2)\n* Complex atheroma with mobile plaque of the descending aorta and\u002For aortic arch (Grade 4 or higher)\n* Evidence of a Cardiac Tumor","100 Years",{"count":337,"type":21},1826,[50],"Randomized controlled trial assessing the safety and efficacy of the LAmbre Plus LAA Closure System to rescue the risk of thromboembolism in patients with non-valvular AF.",[25],[342,343],"Left Atrial Appendage Occlusion","Stroke Risk","2024-08-21",{"date":346,"type":31},"2024-08-23",{"date":348,"type":21},"2024-09-01",{"date":350,"type":21},"2030-01-31",{"name":37,"class":38},""]